The CellRaft™ Technology, which allows researchers to easily sort cells under standard culture conditions resulting in unperturbed phenotypes and high viability, will now be available to researchers and laboratories from multiple sources. Previously, products based on the CellRaft Technology were sold exclusively by QIAGEN under the terms of a 2015 agreement. Going forward, Cell Microsystems will independently commercialize new and existing products and systems that provide optimal application-specific performance to meet the needs of researchers for both RNA/DNA sequencing and clonal propagation applications such as CRISPR/Cas9 transfection.
Click Here for answers to Frequently Asked Questions concerning the new relationship with QIAGEN.
